A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

Conditions

The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.

Experimental: CNTO 1959 (5 mg)
CNTO 1959 5 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
Experimental: CNTO 1959 (15 mg)
CNTO 1959 15 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
Experimental: CNTO 1959 (50 mg)
CNTO 1959 50 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
Experimental: CNTO 1959 (100 mg)
CNTO 1959 100 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
Experimental: CNTO 1959 (200 mg)
CNTO 1959 200 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
Active Comparator: Adalimumab (approved psoriasis dosing)
Adalimumab 80 mg at week 0 followed by 40 mg at week 1 and every second week through Week 39 (i.e., Weeks 3, 5, 7, etc.)
Placebo Comparator: Placebo to CNTO 1959 (100 mg)
Placebo at weeks 0, 4, and 8; then crossover to CNTO 1959 100 mg at Week 16, then every 8 weeks through Week 40

Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 16 [ Time Frame: Week 16 ]

Facility	City	State	ZIP	Site coordinators
-	Birmingham	Alabama	-	-
-	Bakersfield	California	-	-
-	Los Angeles	California	-	-
-	Santa Monica	California	-	-
-	Ocala	Florida	-	-
-	Alpharetta	Georgia	-	-
-	Arlington Heights	Illinois	-	-
-	Skokie	Illinois	-	-
-	Indianapolis	Indiana	-	-
-	Louisville	Kentucky	-	-
-	Andover	Massachusetts	-	-
-	Boston	Massachusetts	-	-
-	St Louis	Missouri	-	-
-	Albuquerque	New Mexico	-	-
-	New York	New York	-	-
-	Portland	Oregon	-	-
-	Pittsburgh	Pennsylvania	-	-
-	Houston	Texas	-	-

By condition

By specialty